Unibest

Pharmaceutical intermediates

Vericiguat Intermediates

2 pharmaceutical intermediates for Vericiguat. Indication: Heart Failure; Shock.

提交项目All intermediates

About Vericiguat

Originator
Bayer
Indication
Heart Failure; Shock
Approved Date
01/19/2021
NCE Patent
01/19/2026
DS/DP
05/19/2031

Available intermediates

2 intermediates currently listed for Vericiguat. Request specifications, documentation or a quotation for any item below.

Vericiguat intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile1350653-26-7//
Phenylazomalononitrile6017-21-6//

Other programs under V

Valbenazine Tosylate (NBI-98854)Varenicline TartrateVelpatasvirVenetoclaxVibegronVilazodone HydrochlorideVONOPRAZAN FUMARATEVoxelotor

Building toward Vericiguat?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →